Stridex Sensitive: the pad label, ingredient versions and count discrepancy

The manufacturer names Sensitive with Aloe and states salicylic acid 0.5% by weight. It separately lists Maximum, Essential and XL Face & Body Pads as other products. Those neighboring names do not authorize transferring their strengths or descriptions into the Sensitive record. Sensitive manufacturer page.

The pad format also remains distinct from a wash, toner or cream. An ingredient percentage cannot erase those identities. The strength comparison explains why even a matching number would not establish the same finished product. Here, the exact Sensitive name and its own active declaration govern, without a potency ranking or a suggestion that another Stridex preparation can fill a missing field.

Blistex’s posted label was updated December 12, 2024. It describes an acne medication and Uses involving acne pimples, blackheads and prevention of new acne pimples. Those statements are more specific than a general claim that every visible pore concern is the same condition. Dated Sensitive label.

FDA explains that active ingredient, purpose, Uses and warnings are separate Drug Facts fields. Applying that distinction here keeps acne-label language separate from a customer’s interpretation of pad residue or skin appearance. FDA field explanation. The date identifies the posted record; it does not establish when a jar was manufactured, what a retailer currently holds or how a particular person will respond.

The current website lists phenoxyethanol, ethylhexylglycerin and witch-hazel water. The 2024 label instead includes DMDM hydantoin, PPG-5-Ceteth-20 and witch-hazel extract. Both lists include fragrance and menthol. These are documented differences between the reviewed records, not a declaration of one combined formula. Website list and dated inactive list.

The review cannot identify which list matches a particular supplied jar without its package information. Nor does the difference alone prove a recall, manufacturing fault or exact reformulation date. Maintaining the two lists preserves a question that a shortened ingredient summary might conceal. A soothing or alcohol-free headline should not replace the full declaration of the actual version under discussion.

The printed active declaration uses 0.5% w/w. The structured strength table separately reports 0.5 g in 100 mL. Those entries use different bases, and the reviewed record does not explain the relationship. This review preserves the discrepancy rather than calculate a conversion or present one as the correction of the other. Printed and structured strength.

The figures are product-strength fields, not an amount a reader should apply. They also do not establish comparative potency against a serum or cleanser. The open question is which specification accurately describes the particular Sensitive preparation. It can be named without reconstructing density, a recipe or an exposure calculation from incomplete public information.

The label’s principal display panel names 90 pads with NDC suffix -2. Its structured packaging table assigns 70 to suffix -2 and 90 to suffix -3. That is a genuine inconsistency within the reviewed record. No inspected jar or tested transaction resolved which package a customer would receive. Panel and packaging entries.

FDA cautions that an NDC identifies a listing and does not denote product approval or agency verification of submitted information. Identifier limitations. It is useful for locating this discrepancy, not for settling it. The Cetaphil record review provides another place to consider package identity without converting a label field into a quality score.

Stridex promotes alcohol-free cleansing and uses visible dirt on a pad as part of its explanation. Visible residue is not a measurement of how many follicles were cleared. The brand’s assurance about avoiding an alcohol-related burn also does not establish that every component will be comfortable for every person. Manufacturer claims.

Both reviewed records retain allergy, irritation and dryness warnings. Those belong beside the reassuring language, without turning the review into application instructions. Label warnings. The Aveeno review discusses another product’s descriptors and warning record. It is a separate document review, not a suggested replacement or a promise about comparative tolerability.

The useful remaining question identifies Sensitive with Aloe, the relevant ingredient version, the strength basis and the exact package count. These are specific document fields. A website price or a broad brand statement would not establish which jar was supplied or reconcile the conflicting label entries. Sensitive page and posted label.

FDA notes that product labeling and ingredients can change, which makes the actual version important. Label-version context. The version guide and format comparison help keep these questions separate. This review records the uncertainty without choosing treatment, inventing a use schedule or suggesting that a label discrepancy predicts a reaction.